{
    "title": "Regeneron's Eylea could return to growth after nod to high-dose version- analysts",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-12428539/Regenerons-Eylea-return-growth-nod-high-dose-version-analysts.html",
    "date": "2023-08-21",
    "keywords": [
        "drug",
        "version",
        "approval",
        "regeneron",
        "growth",
        "vabysmo",
        "analyst",
        "standard",
        "dose",
        "eye",
        "disease",
        "eylea",
        "blockbuster",
        "treatment",
        "street",
        "food",
        "administration",
        "friday",
        "schedule",
        "june",
        "agency",
        "contract",
        "manufacturer",
        "wet",
        "degeneration",
        "macular",
        "edema",
        "retinopathy",
        "gap",
        "blow",
        "copycat",
        "competition",
        "hit",
        "property",
        "exclusivity",
        "bmo",
        "evan",
        "seigerman",
        "franchise",
        "sandler",
        "christopher",
        "raymond",
        "singleuse",
        "vial",
        "price",
        "premium",
        "highdose",
        "cushion",
        "impact",
        "biosimilar",
        "firm",
        "gilead",
        "abbvie",
        "reporting",
        "bengaluru",
        "editing",
        "shinjini",
        "ganguli"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}